Page 19 - Read Online
P. 19

Brown. Rare Dis Orphan Drugs J. 2025;4:21  https://dx.doi.org/10.20517/rdodj.2025.14  Page 15 of 15

                   2020;2:i107-16.  DOI  PubMed  PMC
               70.      Levine SM, Levine E, Taub PJ, Weinberg H. Electrosurgical excision technique for the treatment of multiple cutaneous lesions in
                   neurofibromatosis type I. J Plast Reconstr Aesthet Surg. 2008;61:958-62.  DOI  PubMed
               71.      Verma SK, Riccardi VM, Plotkin SR, et al. Considerations for development of therapies for cutaneous neurofibroma. Neurology.
                   2018;91:S21-30.  DOI
               72.      Sarin KY, Bradshaw M, O’Mara C, et al. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with
                   neurofibromatosis type 1. Sci Adv. 2024;10:eadk4946.  DOI  PubMed  PMC
               73.      Ly I, Romo CG, Gottesman S, et al. Target product profile for cutaneous neurofibromas: clinical trials to prevent, arrest, or regress
                   cutaneous neurofibromas. J Invest Dermatol. 2023;143:1388-96.  DOI  PubMed
               74.      Guiraud M, Bouroubi A, Beauchamp R, et al. Cutaneous neurofibromas: patients’ medical burden, current management and
                   therapeutic expectations: results from an online European patient community survey. Orphanet J Rare Dis. 2019;14:286.  DOI
                   PubMed  PMC
               75.      Passos J, Soares MP, Salgado D, et al. A single-center case study series assessing the effect of selumetinib use in patients with
                   neurofibromatosis-related plexiform neurofibromas. Neurooncol Adv. 2024;6:vdae177.  DOI  PubMed  PMC
               76.      Gross AM, Reid OH, Baldwin LA, et al. Treatment of cutaneous neurofibromas in neurofibromatosis type 1 with mek inhibitor
                   selumetinib: a nonrandomized clinical trial. JAMA Dermatol. 2025;161:533-7.  DOI  PubMed  PMC
               77.      Banerjee J, Allaway RJ, Taroni JN, et al. Integrative analysis identifies candidate tumor microenvironment and intracellular signaling
                   pathways that define tumor heterogeneity in NF1. Genes. 2020;11:226.  DOI  PubMed  PMC
               78.      Mazuelas H, Magallón-Lorenz M, Uriarte-Arrazola I, et al. Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for
                   cutaneous neurofibromas. JCI Insight. 2024:9.  DOI  PubMed  PMC
               79.      In M, Richardson KC, Loewa A, Hedtrich S, Kaessmeyer S, Plendl J. Histological and functional comparisons of four anatomical
                   regions of porcine skin with human abdominal skin. Anat Histol Embryol. 2019;48:207-17.  DOI  PubMed
               80.      Liu Y, Chen JY, Shang HT, et al. Light microscopic, electron microscopic, and immunohistochemical comparison of Bama minipig
                   (Sus scrofa domestica) and human skin. Comp Med. 2010;60:142-8. PubMed  PMC
   14   15   16   17   18   19   20   21   22   23   24